Literature DB >> 10024335

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects.

P Nazzaro1, M Manzari, M Merlo, R Triggiani, A Scarano, L Ciancio, A Pirrelli.   

Abstract

Hypercholesterolemia and hypertension are frequently associated with elevated sympathetic activity. Both are independent cardiovascular risk factors and both affect endothelium-mediated vasodilation. To identify the effects of cholesterol-lowering and antihypertensive treatments on vascular reactivity and vasodilative capacity, we studied 30 hypercholesterolemic hypertensive subjects. They received placebo for 4 weeks, either enalapril or simvastatin for 14 weeks, and, finally, both medications for an additional 14 weeks. Postischemic forearm blood flow (MFBF) and minimal vascular resistance (mFVR) were used as indices of vasodilative capacity and structural vascular damage, respectively. Total (resting-stress-recovery phases) cardiovascular (blood pressure [BP] and heart rate [HR]) and regional hemodynamic (FBF and FVR) reactivity to stressful stimuli were calculated as area-under-the-curve (auc) (valuextime). Compared with baseline levels, simvastatin reduced total (TOT-C) and LDL cholesterol (LDL-C) (1.27 mmol/L, P<0.001 and 1.33 mmol/L, P<0.001, respectively). Enalapril also reduced TOT-C and LDL-C (0.6 mmol/L, P<0.001 and 0.58 mmol/L, P<0.05, respectively). MFBF was increased substantially by both treatments (P<0.001). Enalapril had a greater effect (-1.7 arbitrary units (AU), P<0.001) than simvastatin (-0.6 AU, P<0.05) on mFVR. During stress, FBF increased more with enalapril (4.4 FBFxminutes, P<0.001) than with simvastatin (1.8 FBFxminutes, P<0.01). Conversely, FVR stress response was reduced more with enalapril (9.1 FVRxminutes, P<0.001) than with simvastatin (2.9 FVRxminutes, P<0.01). During combination treatment, a significant (0.001>P<0.05) additive effect on hypercholesterolemia, structural vascular damage, BP, and FVR was shown. The findings suggest that angiotensin-converting enzyme (ACE) inhibition induces a larger reduction than HMG-CoA reductase blockade in vascular reactivity and structural damage in hypercholesterolemic hypertensive subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024335     DOI: 10.1161/01.hyp.33.2.719

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

Review 1.  [Non-lipid effects of statins: myth or fact?].

Authors:  Eleonora Urbauer; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2003

Review 2.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 3.  Hypertension and lipids: lipid factors in the hypertension syndrome.

Authors:  Gary E Sander; Thomas D Giles
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

Review 4.  Statins and blood pressure regulation.

Authors:  C Borghi; M Veronesi; M G Prandin; A Dormi; E Ambrosioni
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 5.  Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease.

Authors:  Jiawei Chen; Jawahar L Mehta
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 6.  Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?

Authors:  Jesse Dawson; Matthew Walters
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

Review 7.  Pleiotropic effects of statins: new therapeutic targets in drug design.

Authors:  Onkar Bedi; Veena Dhawan; P L Sharma; Puneet Kumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

8.  The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial.

Authors:  Jesse Dawson; Terrence J Quinn; Craig Harrow; Kennedy R Lees; Matthew R Walters
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

Review 9.  Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.

Authors:  Claudio Borghi; Ada Dormi; Maddalena Veronesi; Vincenzo Immordino; Ettore Ambrosioni
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

10.  Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients.

Authors:  Ji-Yong Jang; Sang-Hak Lee; Byung Soo Kim; Hong Seog Seo; Woo-Shik Kim; Youngkeun Ahn; Nae-Hee Lee; Kwang Kon Koh; Tae-Soo Kang; Sang-Ho Jo; Bum-Kee Hong; Jang-Ho Bae; Hyoung-Mo Yang; Kwang Soo Cha; Bum Soo Kim; Choong Hwan Kwak; Deok-Kyu Cho; Ung Kim; Joo-Hee Zo; Duk-Hyun Kang; Wook Bum Pyun; Kook Jin Chun; June Namgung; Tae-Joon Cha; Jae-Hyeon Juhn; YeiLi Jung; Yangsoo Jang
Journal:  Korean Circ J       Date:  2015-05-27       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.